SlideShare a Scribd company logo
“So you want to
raise funding and
build a team?”
Few lessons learned
Paul Lammers, MD, MSc
President & CEO
Triumvira Immunologics
InnoTech Meeting, San Antonio, April 12, 2018
“An often heard story…”
InnoTech Meeting, San Antonio, April 12, 2018
Life Sciences Venture Funding ($ millions)
2018 Year to Date
Therapeutics Diagnostics HC Technology HC Services & Other
9,222
860 815
310
87 47 35 17
Total Amount Avg Investment
InnoTech Meeting, San Antonio, April 12, 2018
Paul Lammers, MD, MSc
Brief career overview
 Dutch Biologist & physician by training; spent almost 30 years in
pharma and biotech; all in therapeutics
 Worked in Europe and US; in HQ and local sales-driven
organizations; from big Pharma (n=35,000) to small biotech (n=3)
 Experience in general management, P&L responsibility, business
development, clinical development medical affairs, regulatory
affairs, drug safety, pharmacovigilance, medical information,
quality assurance, contract manufacturing
 Fund raising & corporate transaction experience
 Federal & State grants
 Venture capital firms: strategic and traditional
 IPO on NASDAQ
 Reverse merger
 Moved family 5 times for job opportunities
InnoTech Meeting, San Antonio, April 12, 2018
Therapeutic Modalities:
 Small molecules
 Monoclonal Antibodies
 Recombinant Proteins
 microRNAs
 Engineered T cells
Therapeutic Areas:
 Contraception
 Infertility
 HRT
 Surgical muscle
relaxation
 Cystic Fibrosis
 Seasonal allergic
rhinitis
 Erectile dysfunction
 Multiple Sclerosis
 Oncology
The Mirna Therapeutics Experience
2009-2017
 $ 32 million in Texas State Funding
 $ 77 million in 2 Private Venture rounds
 $ 48 million IPO
 Building a team along the way
 Running a Public Company
 Finished with a Reverse Merger
InnoTech Meeting, San Antonio, April 12, 2018
Austin, Texas
Mirna Therapeutics
Fund Raising & Team Building Chronology
 Mirna Therapeutics spin-out from Asuragen in Austin: received $ 5 million in operating expenses and IP
(became Series A)
 Joined as President & CEO in Nov 2009 (employee nr. 7), with BOD charter to “Turn company into a
Therapeutics Company”
 Dec 2009: Received $ 5.0 Million from Texas Emerging Technology Fund (TETF)
 Started to build the team: hired industry-experienced individuals from Genentech, Pfizer, Azaya; half
the team came from Southern California; n=12 total
 2010: on the road trying to raise $15 million; interest from NEA & Pfizer Ventures, wanted to co-lead a
$25 million round, but ‘data talks’….
 2010: Were successful in first ever Cancer Prevention & Research Institute of Texas (CPRIT) round of
financing: 3/42 companies awarded; received highest award: $10.3 million
InnoTech Meeting, San Antonio, April 12, 2018
Texas State Funding
Great non-dilutive money, but still….
 Texas Emerging Technology Fund (TETF):
 Basically, almost every company that requested money, did get it ($250K - $ 5 M)
 Legislature not in favor; program fizzled out
 CPRIT: “there is pros and cons to everything in life….”
 Key issue to consider in application: “It is not all about the science”
 Great non-dilutive money
 Accounting and auditing requirements are high
InnoTech Meeting, San Antonio, April 12, 2018
Mirna Therapeutics
Fund Raising & Team Building Chronology
 2011: $ 1.5 million (internal) Series B as qualifying round for TETF; could still
convert at first external round at 20% discount (“a really bad deal…”)
 2011-2012: On the road trying to raise a $25 million, first institutional, Series C
round: “Having money in the bank is a double-edged sword”
 October 2012: Raised a $35 million Series C, with Sofinnova, NEA, and Pfizer
Ventures (PVI) as anchor investors, and Osage University Partners, Correlation
Ventures, and internal HNWI as ‘followers’
 Built a very strong Board of Directors: a HUGE advantage!
 Further expanded the team (n=21)
InnoTech Meeting, San Antonio, April 12, 2018
Road to the IPO
“May You Live in Interesting Times”
 2012 – 2014: The world of IPOs is heating up big time, including several of Mirna’s
competitors (Regulus Therapeutics; Dicerna Pharmaceuticals)
InnoTech Meeting, San Antonio, April 12, 2018
 Sept 2013: BOD decides to take Mirna public on NASDAQ
 2013 – 2014:
 Built a bankers syndicate: ideally a mix of ‘bulge bracket’ and niche sell-side
banks
 Meet with a lot of banks; focus on experience and reputation of research
analysts (“be prepared for change”)
 Syndicate I identified:
 Hired a corporate law firm with lots of experience in biotech IPOs
 Latham & Watkins (Menlo Park, CA)
 Weekly S-1 drafting sessions F2F with bankers and lawyers
 S1-drafting is a time- and energy-consuming exercise
Road to the IPO
“May You Live in Interesting Times”
Bookrunners
Leerink Cowen
Co-Managers
RW Baird Wedbush
InnoTech Meeting, San Antonio, April 12, 2018
 June 2014: Mirna files confidentially for IPO (JOBS Act)
 Mid 2014: Banks organize 34 ‘Test The Water’ (TTW) meetings with buy-side
investors:
 NYC, Boston, San Francisco, San Diego, Los Angeles
 Banks collect potential investor feedback after the meetings:
 # 1 issue = The Team !
 Key feedback received:
1. We would like to see several encouraging responses in the clinic
2. Have you considered conducting a mezzanine/cross-over (XO) round of
financing first, before going public?
 Sept 2014: BOD decides to put IPO in hold, pursue XO round first
Road to the IPO
“May You Live in Interesting Times”
InnoTech Meeting, San Antonio, April 12, 2018
Mezzanine Round of Financing
March 2015
 Q4 - 2014: Back on the road trying to raise funding; receive term sheet from Baxter Ventures for
a Series D mezz round on Christmas Eve
 Jan 2015: Start marketing the TS during JP Morgan
 We observe patient responses in Phase 1 trial (PRs; SDs)
 March 2015: Close Series D with good group of investors:
 Baxter Ventures as lead (but only ‘Board Observer’ seat)
 Sofinnova, NEA and PVI as anchors take 50% of round
 XO investors include: Eastern Capital; Celgene, Rock Springs Capital; Sante Ventures,
Morningside, Osage University Partners, Correlation
 Target raise $25 million; over-subscribed: raised $35 million
InnoTech Meeting, San Antonio, April 12, 2018
 Q2-2015: BOD decides to re-initiate the road to an IPO
 Identified a new bankers syndicate (2):
 Bookrunners to split 80%
 Co-Managers’ pity fight over how to split 20%
 Sept 2015: Mirna files S-1 publicly
 IPO Target $ 68 million @ price of $13-15/share
 Mirna hires experienced public company CFO
 Initiate IPO road show:
 69 meetings in 7 days: PA – Baltimore – NYC (2 days) – Boston – San Francisco – Los
Angeles – Denver – San Diego
 Lots of interest, banks excited about building a promising ‘order book’
InnoTech Meeting, San Antonio, April 12, 2018
Road to the IPO
“May You Live in Interesting Times”
Bookrunners
Citi Bank Leerink
Co-Managers
Oppenheimer Cantor Fitzgerald
 Day before Pricing: Martin Shkreli happened: biotech values drops 22% !;
several interested parties back out
 Sept 30, 2015: Mirna closes IPO: gross proceeds of $48 million @ price of
$7.00/share; insiders take 50% to maintain relative percent ownership
 Cost of IPO: ± $ 3.5 million, mostly law firms & printer
 Banks distribute ± $ 3.3 million (7%) amongst the syndicate
 Received 2nd CPRIT Award of $16.7 million on same day as IPO and at same
price
InnoTech Meeting, San Antonio, April 12, 2018
Road to the IPO
“May You Live in Interesting Times”
The End of Mirna
A Reverse Merger
 Immune-related adverse events developed in about 10% of patients treated in a Phase 1 clinical
trial, including life-threatening Cytokine Release Syndrome
 Decision made in Sept 2016 to stop the program; Board accepted my suggestion to not try to
discover a new delivery method (despite $ 60 million in the bank)
 From 36 employees down to 12, then down to 4 till the end
 Oct 2016 – August 2017: Wedbush hired to manage a potential strategic transaction process
 Initial interest was enormous: ± 140 companies; Meetings held with 49 (!) companies
 Funnel evaluation process ended with 5 lead companies; Synlogic (Cambridge, MA) selected
 Drafting S-4 more work than S-1; Reverse merger completed August 2017
InnoTech Meeting, San Antonio, April 12, 2018
Few Lessons Learned….
InnoTech Meeting, San Antonio, April 12, 2018
Building your Team (‘it all depends…’)
The small biotech conundrum:
“You need a team to raise the money, you need money to raise a team”
InnoTech Meeting, San Antonio, April 12, 2018
Initial Critical Functions
Finance
CMO
CSO or CTO
Preclinical Development
Project & Outsource Manager
R&D scientists
Initially Not So Critical Functions
Regulatory Affairs
Clinical Operations
Manufacturing
Business Development
Administrative Assistant
Outsource
Do it yourself
“Will Travel for Food”
InnoTech Meeting, San Antonio, April 12, 2018
“If you want to raise money
for your company, you live in
Boston, New York,
and San Francisco”
“Will Travel For Food”
 2014 - 2015: ± 150 investor meetings
 JP Morgan Healthcare Conference (SFO)
 BIO CEO Conference (NYC)
 BIO Investor Forum (SFO)
 BIO-Europe
 BIO Sofinnova Conference (JP)
 Bio Int’l Convention (cave: do not present)
 Sachs Investor Forum
 Biotech Showcase (SFO)
 MedPace Forum (SFO)
 Etc.
InnoTech Meeting, San Antonio, April 12, 2018
• Be prepared to present in front of a tiny audience
• Be prepared to only have service providers attend your presentation,
just to introduce themselves to you after the talk
• Be prepared to pay about $3,000 for each presentation
“Will Travel For Food”
All of the Other Meetings
 Boston Biotech CEO meeting (a lot of peers, a decent number of investors)
 NY Biotech CEO meeting (a lot of peers, a decent number of investors)
 Therapeutic Area meetings: e.g., for oncology
 AACR
 ASCO
 ASH
 SITC
 IO meetings
 Texas Life Sciences Venture Forum
 Texas Life Sciences CEO Meeting
 Etc.
InnoTech Meeting, San Antonio, April 12, 2018
The Investor Pitch
“Practice Makes Perfect”
 Be prepared for presentations of:
60 - 45 - 30 - 20 – 15 – 8 – 4 minutes
 “If you cannot do PowerPoint, you will not be successful in business”
 “I know you love the science, but easy on the data dump” (back-up slides)
 Be prepared to give the same talk 10 times in a row (and last one should
sound as enthusiastic as first one)
 Tell yourself “You can do it, You can do it, and….You can do it”
InnoTech Meeting, San Antonio, April 12, 2018
‘ridiculous territory’
So You Want To Be A Public Company CEO…?
Be Careful of What you Wish for
 Pay is bigger, but so is personal accountability….(D&O insurance!)
 Awesome in good times, but we all know, those normally don’t last….
 Be careful what you promise, because if you don’t deliver, Wall Street can be ruthless….
 Institutional investors are mostly great, but retail investors can a be a royal pain…
 Please don’t watch your company’s ticker symbol more than once a day, will drive you
crazy..
 ‘Stocks go up on rumors, go down on news’, so hold on for the ride!
InnoTech Meeting, San Antonio, April 12, 2018
PATIENCE
InnoTech Meeting, San Antonio, April 12, 2018
PERSEVERANCE
BUILD TRUST
BE HONEST & OPEN
STAMINA
BUILD CONNECTIONS
SHOW CONFIDENCE
The Bottom Line

More Related Content

Similar to "So you want to raise funding and build a team?"

Start up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
Start up health Insights Digital Health Funding Rankings 2016 Mid Year RankingStart up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
Start up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
Dexter Wee
 
StartUp Health Insights 2016 Midyear Report
StartUp Health Insights 2016 Midyear ReportStartUp Health Insights 2016 Midyear Report
StartUp Health Insights 2016 Midyear Report
StartUp Health
 
Retail SPAC Investors in the SPACBoom 2020-2022.pdf
Retail SPAC Investors in the SPACBoom 2020-2022.pdfRetail SPAC Investors in the SPACBoom 2020-2022.pdf
Retail SPAC Investors in the SPACBoom 2020-2022.pdf
Drs Alcanne Houtzaager MA
 
How GenSpera operates as a virtual company
How GenSpera operates as a virtual companyHow GenSpera operates as a virtual company
How GenSpera operates as a virtual company
Alan Weinkrantz
 
Startup Health | HealthTech Funding | Q1 2017
Startup Health | HealthTech Funding | Q1 2017Startup Health | HealthTech Funding | Q1 2017
Startup Health | HealthTech Funding | Q1 2017
Galen Growth
 
Innovation Louisiana 2015 Conference Program
Innovation Louisiana 2015 Conference ProgramInnovation Louisiana 2015 Conference Program
Innovation Louisiana 2015 Conference Program
neworleansbio
 
StartUp_Health_Insights_2015
StartUp_Health_Insights_2015StartUp_Health_Insights_2015
StartUp_Health_Insights_2015Mateus Baptista
 
StartUp Health Insights Funding Report Q1 2017
StartUp Health Insights Funding Report Q1 2017StartUp Health Insights Funding Report Q1 2017
StartUp Health Insights Funding Report Q1 2017
StartUp Health
 
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
ideaport
 
Tracxn Research - BioPharma Report, May 2017
Tracxn Research - BioPharma Report, May 2017Tracxn Research - BioPharma Report, May 2017
Tracxn Research - BioPharma Report, May 2017
Tracxn
 
Corporate Innovation 101
Corporate Innovation 101Corporate Innovation 101
Corporate Innovation 101
Asher Siddiqui
 
Cid4 presentation for 2014 meyers class
Cid4  presentation for 2014 meyers class Cid4  presentation for 2014 meyers class
Cid4 presentation for 2014 meyers class
Arlen Meyers, MD, MBA
 
Assignment 2 New Venture
Assignment 2 New VentureAssignment 2 New Venture
Assignment 2 New Venture
Tracy Clark
 
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
StartUp Health
 
Raising money for_life_sci_co_02-23-2015
Raising money for_life_sci_co_02-23-2015Raising money for_life_sci_co_02-23-2015
Raising money for_life_sci_co_02-23-2015
James Stuber
 
Responsible Investing: Alternative Perspectives to the Conventional View
Responsible Investing: Alternative Perspectives to the Conventional ViewResponsible Investing: Alternative Perspectives to the Conventional View
Responsible Investing: Alternative Perspectives to the Conventional View
Colin Habberton
 
StartUp Health Insights 2016 Q3 Report
StartUp Health Insights 2016 Q3 ReportStartUp Health Insights 2016 Q3 Report
StartUp Health Insights 2016 Q3 Report
StartUp Health
 
2017 StartUp Health Insights Year End Report
2017 StartUp Health Insights Year End Report2017 StartUp Health Insights Year End Report
2017 StartUp Health Insights Year End Report
StartUp Health
 
2015-annual-investment-report
2015-annual-investment-report2015-annual-investment-report
2015-annual-investment-reportCheryl Matter
 
STARTUP-PPT.pptx
STARTUP-PPT.pptxSTARTUP-PPT.pptx
STARTUP-PPT.pptx
saran2011
 

Similar to "So you want to raise funding and build a team?" (20)

Start up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
Start up health Insights Digital Health Funding Rankings 2016 Mid Year RankingStart up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
Start up health Insights Digital Health Funding Rankings 2016 Mid Year Ranking
 
StartUp Health Insights 2016 Midyear Report
StartUp Health Insights 2016 Midyear ReportStartUp Health Insights 2016 Midyear Report
StartUp Health Insights 2016 Midyear Report
 
Retail SPAC Investors in the SPACBoom 2020-2022.pdf
Retail SPAC Investors in the SPACBoom 2020-2022.pdfRetail SPAC Investors in the SPACBoom 2020-2022.pdf
Retail SPAC Investors in the SPACBoom 2020-2022.pdf
 
How GenSpera operates as a virtual company
How GenSpera operates as a virtual companyHow GenSpera operates as a virtual company
How GenSpera operates as a virtual company
 
Startup Health | HealthTech Funding | Q1 2017
Startup Health | HealthTech Funding | Q1 2017Startup Health | HealthTech Funding | Q1 2017
Startup Health | HealthTech Funding | Q1 2017
 
Innovation Louisiana 2015 Conference Program
Innovation Louisiana 2015 Conference ProgramInnovation Louisiana 2015 Conference Program
Innovation Louisiana 2015 Conference Program
 
StartUp_Health_Insights_2015
StartUp_Health_Insights_2015StartUp_Health_Insights_2015
StartUp_Health_Insights_2015
 
StartUp Health Insights Funding Report Q1 2017
StartUp Health Insights Funding Report Q1 2017StartUp Health Insights Funding Report Q1 2017
StartUp Health Insights Funding Report Q1 2017
 
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
From Impact Investment to Crowdfunding | Rosalinda Natividad (@Refresh 2017 b...
 
Tracxn Research - BioPharma Report, May 2017
Tracxn Research - BioPharma Report, May 2017Tracxn Research - BioPharma Report, May 2017
Tracxn Research - BioPharma Report, May 2017
 
Corporate Innovation 101
Corporate Innovation 101Corporate Innovation 101
Corporate Innovation 101
 
Cid4 presentation for 2014 meyers class
Cid4  presentation for 2014 meyers class Cid4  presentation for 2014 meyers class
Cid4 presentation for 2014 meyers class
 
Assignment 2 New Venture
Assignment 2 New VentureAssignment 2 New Venture
Assignment 2 New Venture
 
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
StartUp Health Insights Global Digital Health Funding Report: 2018 Year End R...
 
Raising money for_life_sci_co_02-23-2015
Raising money for_life_sci_co_02-23-2015Raising money for_life_sci_co_02-23-2015
Raising money for_life_sci_co_02-23-2015
 
Responsible Investing: Alternative Perspectives to the Conventional View
Responsible Investing: Alternative Perspectives to the Conventional ViewResponsible Investing: Alternative Perspectives to the Conventional View
Responsible Investing: Alternative Perspectives to the Conventional View
 
StartUp Health Insights 2016 Q3 Report
StartUp Health Insights 2016 Q3 ReportStartUp Health Insights 2016 Q3 Report
StartUp Health Insights 2016 Q3 Report
 
2017 StartUp Health Insights Year End Report
2017 StartUp Health Insights Year End Report2017 StartUp Health Insights Year End Report
2017 StartUp Health Insights Year End Report
 
2015-annual-investment-report
2015-annual-investment-report2015-annual-investment-report
2015-annual-investment-report
 
STARTUP-PPT.pptx
STARTUP-PPT.pptxSTARTUP-PPT.pptx
STARTUP-PPT.pptx
 

More from InnoTech

Artificial Intelligence is Maturing
Artificial Intelligence is MaturingArtificial Intelligence is Maturing
Artificial Intelligence is Maturing
InnoTech
 
What is AI without Data?
What is AI without Data?What is AI without Data?
What is AI without Data?
InnoTech
 
Courageous Leadership - When it Matters Most
Courageous Leadership - When it Matters MostCourageous Leadership - When it Matters Most
Courageous Leadership - When it Matters Most
InnoTech
 
The Gathering Storm
The Gathering StormThe Gathering Storm
The Gathering Storm
InnoTech
 
Sql Server tips from the field
Sql Server tips from the fieldSql Server tips from the field
Sql Server tips from the field
InnoTech
 
Quantum Computing and its security implications
Quantum Computing and its security implicationsQuantum Computing and its security implications
Quantum Computing and its security implications
InnoTech
 
Converged Infrastructure
Converged InfrastructureConverged Infrastructure
Converged Infrastructure
InnoTech
 
Making the most out of collaboration with Office 365
Making the most out of collaboration with Office 365Making the most out of collaboration with Office 365
Making the most out of collaboration with Office 365
InnoTech
 
Blockchain use cases and case studies
Blockchain use cases and case studiesBlockchain use cases and case studies
Blockchain use cases and case studies
InnoTech
 
Blockchain: Exploring the Fundamentals and Promising Potential
Blockchain: Exploring the Fundamentals and Promising Potential Blockchain: Exploring the Fundamentals and Promising Potential
Blockchain: Exploring the Fundamentals and Promising Potential
InnoTech
 
Business leaders are engaging labor differently - Is your IT ready?
Business leaders are engaging labor differently - Is your IT ready?Business leaders are engaging labor differently - Is your IT ready?
Business leaders are engaging labor differently - Is your IT ready?
InnoTech
 
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
InnoTech
 
Using Business Intelligence to Bring Your Data to Life
Using Business Intelligence to Bring Your Data to LifeUsing Business Intelligence to Bring Your Data to Life
Using Business Intelligence to Bring Your Data to Life
InnoTech
 
User requirements is a fallacy
User requirements is a fallacyUser requirements is a fallacy
User requirements is a fallacy
InnoTech
 
What I Wish I Knew Before I Signed that Contract - San Antonio
What I Wish I Knew Before I Signed that Contract - San Antonio What I Wish I Knew Before I Signed that Contract - San Antonio
What I Wish I Knew Before I Signed that Contract - San Antonio
InnoTech
 
Disaster Recovery Plan - Quorum
Disaster Recovery Plan - QuorumDisaster Recovery Plan - Quorum
Disaster Recovery Plan - Quorum
InnoTech
 
Share point saturday access services 2015 final 2
Share point saturday access services 2015 final 2Share point saturday access services 2015 final 2
Share point saturday access services 2015 final 2
InnoTech
 
Sp tech festdallas - office 365 groups - planner session
Sp tech festdallas - office 365 groups - planner sessionSp tech festdallas - office 365 groups - planner session
Sp tech festdallas - office 365 groups - planner session
InnoTech
 
Power apps presentation
Power apps presentationPower apps presentation
Power apps presentation
InnoTech
 
Using rest to create responsive html 5 share point intranets
Using rest to create responsive html 5 share point intranetsUsing rest to create responsive html 5 share point intranets
Using rest to create responsive html 5 share point intranets
InnoTech
 

More from InnoTech (20)

Artificial Intelligence is Maturing
Artificial Intelligence is MaturingArtificial Intelligence is Maturing
Artificial Intelligence is Maturing
 
What is AI without Data?
What is AI without Data?What is AI without Data?
What is AI without Data?
 
Courageous Leadership - When it Matters Most
Courageous Leadership - When it Matters MostCourageous Leadership - When it Matters Most
Courageous Leadership - When it Matters Most
 
The Gathering Storm
The Gathering StormThe Gathering Storm
The Gathering Storm
 
Sql Server tips from the field
Sql Server tips from the fieldSql Server tips from the field
Sql Server tips from the field
 
Quantum Computing and its security implications
Quantum Computing and its security implicationsQuantum Computing and its security implications
Quantum Computing and its security implications
 
Converged Infrastructure
Converged InfrastructureConverged Infrastructure
Converged Infrastructure
 
Making the most out of collaboration with Office 365
Making the most out of collaboration with Office 365Making the most out of collaboration with Office 365
Making the most out of collaboration with Office 365
 
Blockchain use cases and case studies
Blockchain use cases and case studiesBlockchain use cases and case studies
Blockchain use cases and case studies
 
Blockchain: Exploring the Fundamentals and Promising Potential
Blockchain: Exploring the Fundamentals and Promising Potential Blockchain: Exploring the Fundamentals and Promising Potential
Blockchain: Exploring the Fundamentals and Promising Potential
 
Business leaders are engaging labor differently - Is your IT ready?
Business leaders are engaging labor differently - Is your IT ready?Business leaders are engaging labor differently - Is your IT ready?
Business leaders are engaging labor differently - Is your IT ready?
 
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
AI 3.0: Is it Finally Time for Artificial Intelligence and Sensor Networks to...
 
Using Business Intelligence to Bring Your Data to Life
Using Business Intelligence to Bring Your Data to LifeUsing Business Intelligence to Bring Your Data to Life
Using Business Intelligence to Bring Your Data to Life
 
User requirements is a fallacy
User requirements is a fallacyUser requirements is a fallacy
User requirements is a fallacy
 
What I Wish I Knew Before I Signed that Contract - San Antonio
What I Wish I Knew Before I Signed that Contract - San Antonio What I Wish I Knew Before I Signed that Contract - San Antonio
What I Wish I Knew Before I Signed that Contract - San Antonio
 
Disaster Recovery Plan - Quorum
Disaster Recovery Plan - QuorumDisaster Recovery Plan - Quorum
Disaster Recovery Plan - Quorum
 
Share point saturday access services 2015 final 2
Share point saturday access services 2015 final 2Share point saturday access services 2015 final 2
Share point saturday access services 2015 final 2
 
Sp tech festdallas - office 365 groups - planner session
Sp tech festdallas - office 365 groups - planner sessionSp tech festdallas - office 365 groups - planner session
Sp tech festdallas - office 365 groups - planner session
 
Power apps presentation
Power apps presentationPower apps presentation
Power apps presentation
 
Using rest to create responsive html 5 share point intranets
Using rest to create responsive html 5 share point intranetsUsing rest to create responsive html 5 share point intranets
Using rest to create responsive html 5 share point intranets
 

Recently uploaded

POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 

Recently uploaded (20)

POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 

"So you want to raise funding and build a team?"

  • 1. “So you want to raise funding and build a team?” Few lessons learned Paul Lammers, MD, MSc President & CEO Triumvira Immunologics InnoTech Meeting, San Antonio, April 12, 2018
  • 2. “An often heard story…” InnoTech Meeting, San Antonio, April 12, 2018
  • 3. Life Sciences Venture Funding ($ millions) 2018 Year to Date Therapeutics Diagnostics HC Technology HC Services & Other 9,222 860 815 310 87 47 35 17 Total Amount Avg Investment InnoTech Meeting, San Antonio, April 12, 2018
  • 4. Paul Lammers, MD, MSc Brief career overview  Dutch Biologist & physician by training; spent almost 30 years in pharma and biotech; all in therapeutics  Worked in Europe and US; in HQ and local sales-driven organizations; from big Pharma (n=35,000) to small biotech (n=3)  Experience in general management, P&L responsibility, business development, clinical development medical affairs, regulatory affairs, drug safety, pharmacovigilance, medical information, quality assurance, contract manufacturing  Fund raising & corporate transaction experience  Federal & State grants  Venture capital firms: strategic and traditional  IPO on NASDAQ  Reverse merger  Moved family 5 times for job opportunities InnoTech Meeting, San Antonio, April 12, 2018 Therapeutic Modalities:  Small molecules  Monoclonal Antibodies  Recombinant Proteins  microRNAs  Engineered T cells Therapeutic Areas:  Contraception  Infertility  HRT  Surgical muscle relaxation  Cystic Fibrosis  Seasonal allergic rhinitis  Erectile dysfunction  Multiple Sclerosis  Oncology
  • 5. The Mirna Therapeutics Experience 2009-2017  $ 32 million in Texas State Funding  $ 77 million in 2 Private Venture rounds  $ 48 million IPO  Building a team along the way  Running a Public Company  Finished with a Reverse Merger InnoTech Meeting, San Antonio, April 12, 2018 Austin, Texas
  • 6. Mirna Therapeutics Fund Raising & Team Building Chronology  Mirna Therapeutics spin-out from Asuragen in Austin: received $ 5 million in operating expenses and IP (became Series A)  Joined as President & CEO in Nov 2009 (employee nr. 7), with BOD charter to “Turn company into a Therapeutics Company”  Dec 2009: Received $ 5.0 Million from Texas Emerging Technology Fund (TETF)  Started to build the team: hired industry-experienced individuals from Genentech, Pfizer, Azaya; half the team came from Southern California; n=12 total  2010: on the road trying to raise $15 million; interest from NEA & Pfizer Ventures, wanted to co-lead a $25 million round, but ‘data talks’….  2010: Were successful in first ever Cancer Prevention & Research Institute of Texas (CPRIT) round of financing: 3/42 companies awarded; received highest award: $10.3 million InnoTech Meeting, San Antonio, April 12, 2018
  • 7. Texas State Funding Great non-dilutive money, but still….  Texas Emerging Technology Fund (TETF):  Basically, almost every company that requested money, did get it ($250K - $ 5 M)  Legislature not in favor; program fizzled out  CPRIT: “there is pros and cons to everything in life….”  Key issue to consider in application: “It is not all about the science”  Great non-dilutive money  Accounting and auditing requirements are high InnoTech Meeting, San Antonio, April 12, 2018
  • 8. Mirna Therapeutics Fund Raising & Team Building Chronology  2011: $ 1.5 million (internal) Series B as qualifying round for TETF; could still convert at first external round at 20% discount (“a really bad deal…”)  2011-2012: On the road trying to raise a $25 million, first institutional, Series C round: “Having money in the bank is a double-edged sword”  October 2012: Raised a $35 million Series C, with Sofinnova, NEA, and Pfizer Ventures (PVI) as anchor investors, and Osage University Partners, Correlation Ventures, and internal HNWI as ‘followers’  Built a very strong Board of Directors: a HUGE advantage!  Further expanded the team (n=21) InnoTech Meeting, San Antonio, April 12, 2018
  • 9. Road to the IPO “May You Live in Interesting Times”  2012 – 2014: The world of IPOs is heating up big time, including several of Mirna’s competitors (Regulus Therapeutics; Dicerna Pharmaceuticals) InnoTech Meeting, San Antonio, April 12, 2018
  • 10.  Sept 2013: BOD decides to take Mirna public on NASDAQ  2013 – 2014:  Built a bankers syndicate: ideally a mix of ‘bulge bracket’ and niche sell-side banks  Meet with a lot of banks; focus on experience and reputation of research analysts (“be prepared for change”)  Syndicate I identified:  Hired a corporate law firm with lots of experience in biotech IPOs  Latham & Watkins (Menlo Park, CA)  Weekly S-1 drafting sessions F2F with bankers and lawyers  S1-drafting is a time- and energy-consuming exercise Road to the IPO “May You Live in Interesting Times” Bookrunners Leerink Cowen Co-Managers RW Baird Wedbush InnoTech Meeting, San Antonio, April 12, 2018
  • 11.  June 2014: Mirna files confidentially for IPO (JOBS Act)  Mid 2014: Banks organize 34 ‘Test The Water’ (TTW) meetings with buy-side investors:  NYC, Boston, San Francisco, San Diego, Los Angeles  Banks collect potential investor feedback after the meetings:  # 1 issue = The Team !  Key feedback received: 1. We would like to see several encouraging responses in the clinic 2. Have you considered conducting a mezzanine/cross-over (XO) round of financing first, before going public?  Sept 2014: BOD decides to put IPO in hold, pursue XO round first Road to the IPO “May You Live in Interesting Times” InnoTech Meeting, San Antonio, April 12, 2018
  • 12. Mezzanine Round of Financing March 2015  Q4 - 2014: Back on the road trying to raise funding; receive term sheet from Baxter Ventures for a Series D mezz round on Christmas Eve  Jan 2015: Start marketing the TS during JP Morgan  We observe patient responses in Phase 1 trial (PRs; SDs)  March 2015: Close Series D with good group of investors:  Baxter Ventures as lead (but only ‘Board Observer’ seat)  Sofinnova, NEA and PVI as anchors take 50% of round  XO investors include: Eastern Capital; Celgene, Rock Springs Capital; Sante Ventures, Morningside, Osage University Partners, Correlation  Target raise $25 million; over-subscribed: raised $35 million InnoTech Meeting, San Antonio, April 12, 2018
  • 13.  Q2-2015: BOD decides to re-initiate the road to an IPO  Identified a new bankers syndicate (2):  Bookrunners to split 80%  Co-Managers’ pity fight over how to split 20%  Sept 2015: Mirna files S-1 publicly  IPO Target $ 68 million @ price of $13-15/share  Mirna hires experienced public company CFO  Initiate IPO road show:  69 meetings in 7 days: PA – Baltimore – NYC (2 days) – Boston – San Francisco – Los Angeles – Denver – San Diego  Lots of interest, banks excited about building a promising ‘order book’ InnoTech Meeting, San Antonio, April 12, 2018 Road to the IPO “May You Live in Interesting Times” Bookrunners Citi Bank Leerink Co-Managers Oppenheimer Cantor Fitzgerald
  • 14.  Day before Pricing: Martin Shkreli happened: biotech values drops 22% !; several interested parties back out  Sept 30, 2015: Mirna closes IPO: gross proceeds of $48 million @ price of $7.00/share; insiders take 50% to maintain relative percent ownership  Cost of IPO: ± $ 3.5 million, mostly law firms & printer  Banks distribute ± $ 3.3 million (7%) amongst the syndicate  Received 2nd CPRIT Award of $16.7 million on same day as IPO and at same price InnoTech Meeting, San Antonio, April 12, 2018 Road to the IPO “May You Live in Interesting Times”
  • 15. The End of Mirna A Reverse Merger  Immune-related adverse events developed in about 10% of patients treated in a Phase 1 clinical trial, including life-threatening Cytokine Release Syndrome  Decision made in Sept 2016 to stop the program; Board accepted my suggestion to not try to discover a new delivery method (despite $ 60 million in the bank)  From 36 employees down to 12, then down to 4 till the end  Oct 2016 – August 2017: Wedbush hired to manage a potential strategic transaction process  Initial interest was enormous: ± 140 companies; Meetings held with 49 (!) companies  Funnel evaluation process ended with 5 lead companies; Synlogic (Cambridge, MA) selected  Drafting S-4 more work than S-1; Reverse merger completed August 2017 InnoTech Meeting, San Antonio, April 12, 2018
  • 16. Few Lessons Learned…. InnoTech Meeting, San Antonio, April 12, 2018
  • 17. Building your Team (‘it all depends…’) The small biotech conundrum: “You need a team to raise the money, you need money to raise a team” InnoTech Meeting, San Antonio, April 12, 2018 Initial Critical Functions Finance CMO CSO or CTO Preclinical Development Project & Outsource Manager R&D scientists Initially Not So Critical Functions Regulatory Affairs Clinical Operations Manufacturing Business Development Administrative Assistant Outsource Do it yourself
  • 18. “Will Travel for Food” InnoTech Meeting, San Antonio, April 12, 2018 “If you want to raise money for your company, you live in Boston, New York, and San Francisco”
  • 19. “Will Travel For Food”  2014 - 2015: ± 150 investor meetings  JP Morgan Healthcare Conference (SFO)  BIO CEO Conference (NYC)  BIO Investor Forum (SFO)  BIO-Europe  BIO Sofinnova Conference (JP)  Bio Int’l Convention (cave: do not present)  Sachs Investor Forum  Biotech Showcase (SFO)  MedPace Forum (SFO)  Etc. InnoTech Meeting, San Antonio, April 12, 2018 • Be prepared to present in front of a tiny audience • Be prepared to only have service providers attend your presentation, just to introduce themselves to you after the talk • Be prepared to pay about $3,000 for each presentation
  • 20. “Will Travel For Food” All of the Other Meetings  Boston Biotech CEO meeting (a lot of peers, a decent number of investors)  NY Biotech CEO meeting (a lot of peers, a decent number of investors)  Therapeutic Area meetings: e.g., for oncology  AACR  ASCO  ASH  SITC  IO meetings  Texas Life Sciences Venture Forum  Texas Life Sciences CEO Meeting  Etc. InnoTech Meeting, San Antonio, April 12, 2018
  • 21. The Investor Pitch “Practice Makes Perfect”  Be prepared for presentations of: 60 - 45 - 30 - 20 – 15 – 8 – 4 minutes  “If you cannot do PowerPoint, you will not be successful in business”  “I know you love the science, but easy on the data dump” (back-up slides)  Be prepared to give the same talk 10 times in a row (and last one should sound as enthusiastic as first one)  Tell yourself “You can do it, You can do it, and….You can do it” InnoTech Meeting, San Antonio, April 12, 2018 ‘ridiculous territory’
  • 22. So You Want To Be A Public Company CEO…? Be Careful of What you Wish for  Pay is bigger, but so is personal accountability….(D&O insurance!)  Awesome in good times, but we all know, those normally don’t last….  Be careful what you promise, because if you don’t deliver, Wall Street can be ruthless….  Institutional investors are mostly great, but retail investors can a be a royal pain…  Please don’t watch your company’s ticker symbol more than once a day, will drive you crazy..  ‘Stocks go up on rumors, go down on news’, so hold on for the ride! InnoTech Meeting, San Antonio, April 12, 2018
  • 23. PATIENCE InnoTech Meeting, San Antonio, April 12, 2018 PERSEVERANCE BUILD TRUST BE HONEST & OPEN STAMINA BUILD CONNECTIONS SHOW CONFIDENCE The Bottom Line